Market Place
Sourcing Support
All News #Library
Biotech
FDA Sets PDUFA For Hansa`s Kidney Transplant Med
05 Mar 2026 //
FIERCE PHARMA
FDA Sets PDUFA Date for Hansa Bio`s Imlifidase BLA on Dec. 19
05 Mar 2026 //
PHARMIWEB
Hansa Bio Releases 2025 Q4 & Full-Year Financial Result
11 Feb 2026 //
PHARMIWEB
Hansa Bio Seeks FDA Approval For Imlifidase In Kidney Transplant
20 Dec 2025 //
PR NEWSWIRE
Hansa Eyes FDA Nod After Kidney Transplant Drug Succeeds in Trial
27 Sep 2025 //
PRESS RELEASE
Hansa Biopharma Completes Enrollment in Imlifidase Ph 3 Trial
05 Dec 2024 //
PR NEWSWIRE
Hansa Biopharma Reports Positive NICE-01 Trial Results
08 Oct 2024 //
PHARMABIZ
Hansa Biopharma Completes Randomization in Pivotal Phase 3 US ConfIdeS Trial
31 May 2024 //
PR NEWSWIRE
Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 in patients with AMR
14 Dec 2023 //
PR NEWSWIRE
Imlifidase demonstrated positive safety efficacy outcomes phase 2 trial in GBS
06 Dec 2023 //
PR NEWSWIRE
First patient treated with imlifidase in an investigator-initiated Phase 2 study
19 Jul 2023 //
PR NEWSWIRE
Hansa announces first patient dosed imlifidase in a global pivotal ph3 trial
30 May 2023 //
PR NEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.